Relmada Therapeutics Inc Stock OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
Mar. 19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 3M | Capitalization | 118M |
---|---|---|---|---|---|
Net income 2024 * | -112M | Net income 2025 * | -120M | EV / Sales 2024 * | - |
Net cash position 2024 * | 203M | Net cash position 2025 * | 124M | EV / Sales 2025 * | -1.95 x |
P/E ratio 2024 * |
-1.28
x | P/E ratio 2025 * |
-1.66
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.76% |
Latest transcript on Relmada Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 12-05-30 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 15-07-13 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
1st Jan change | Capi. | |
---|---|---|
-0.49% | 103B | |
+3.31% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-22.87% | 13.68B | |
+6.32% | 13.44B | |
+21.46% | 10.98B |